Exploring the Use of NUDT5 Inhibitors to Treat Breast Cancer
Monday, 23 August 2021
NUDT5 is found to be overexpressed in certain cancers in humans Could NUDT5 inhibitors lead to new cancer treatments? NUDIX hydrolases are a superfamily of enzymes are found in all classes of organisms and are responsible for hydrolyzing modified nucleoside diphosphates. One of the most well-studied NUDIX hydrolases is NUDT1 (also known as MTH1); it
- Published in Emerging Targets, HTS Assays, Products
No Comments
The Role of CD38 Activity in the Impaired Immune Response
Tuesday, 10 August 2021
Cluster of differentiation 38 (CD38) is a multifaceted protein contributing to immune response, cell adhesion, and signal transduction. Furthermore, it plays a vital role in calcium signaling, which is necessary for further cell signaling. Calcium acts as a second messenger regulating muscle contraction, cell growth, fertilization, and cellular motility, to name a few areas of
- Published in Emerging Targets, HTS Assays, Innate Immunity
Targeting Adenosine Kinase in the Fight Against Neurological Disorders
Monday, 28 June 2021
Could targeting Adenosine Kinase help lead to treatments for neurological disorders and chronic pain? Adenosine, one of four nucleoside building blocks to DNA and RNA, has a shielding effect on a wide range of conditions, including inflammation, various forms of neuronal hyperexcitability, and/or toxicity, including hypoxia, seizures, and chronic pain. This cellular activity modulator brings
- Published in Emerging Targets, Innate Immunity, Neurodegenerative Diseases
NSP13 Inhibitors for the Potential Treatment of COVID-19
Monday, 14 June 2021
Could NSP13 be the target to help treat some respiratory infections such as SARS-CoV-2? Respiratory diseases caused by coronaviruses (CoVs) vary in symptoms, severity, and risk. Typically, symptoms are mild and known as the common cold, while others are more severe and lead to pneumonia or bronchitis, chest pains, and possibly death. SARS-CoV and MERS-CoV
- Published in Emerging Targets, HTS Assays, Innate Immunity
Using a PKR Inhibitor Assay in the Fight Against Viruses
Tuesday, 01 June 2021
Can a novel PKR inhibitor help lead to new treatments for viral infections? – While the human immune response is astounding and works hard to keep us alive in the face of the many germs we encounter daily, it is exceedingly complex. Unlike the adaptive immune response, the innate response acts quickly. It is considered
- Published in Emerging Targets, HTS Assays, Innate Immunity
TREX1 Inhibitor Assays May Aid the Discovery Novel HIV Treatments
Monday, 17 May 2021
TREX1 Inhibitor assays could help move things forward for cancer and HIV treatments. – The immune system of humans is remarkable. Unlike the adaptive immune response, the innate immune response is quick and is considered the first line of defense against pathogens and foreign DNA. This foreign material can come from pathogens, tumor cells, or
- Published in Company, Emerging Targets
Can DDX3 Inhibitors Lead to the Discovery of Antiviral Therapies?
Tuesday, 04 May 2021
DDX3 inhibitors could unlock new treatments for viral diseases. The human immune response is extraordinary and incredibly complex. As the first line of defense against pathogens and foreign DNA, the innate response acts quickly. Viruses activate innate immunity as the host has proteins that recognize viral components. The innate immune response relies on several cell
- Published in Emerging Targets, HTS Assays
New Publication by the Scientists at BellBrook Labs – Development of a High-Throughput Assay to Identify Inhibitors of ENPP1
Thursday, 11 February 2021
BellBrook scientist Meera Kumar and Robert Lowery were recently published in SLAS Discovery for their work entitled Development of a High-Throughput Assay to Identify Inhibitors of ENPP1. Ectonucleotide pyrophosphatase/phosphodiesterase 1 or ENNP1 has recently become a target for cancer immunotherapy. ENNP1 hydrolyzes nucleotides such as cGAMP and ATP. Cytosolic DNA is a trigger for the
- Published in Emerging Targets, HTS Assays, News
A Search for NLRP3 Inhibitors to Fight Autoimmune Disease
Wednesday, 08 July 2020
Can NLRP3 inhibitors help treat autoimmune disease? – The human immune response is complicated and we continue to discover pathways involved that add to the complexity. Different than the adaptive immune response, the innate response acts quickly and is considered the first line of defense against pathogens and foreign DNA. In order to do its
- Published in Emerging Targets
ST6GAL1 Drug Discovery to Combat Cancer
Wednesday, 08 January 2020
The number of cancer hallmarks has increased as the knowledge and understanding of the disease progress. As many of us already know, the basic characteristic is a mutation that causes uncontrollable cell growth causing a tumor. Cancer is truly a multi-step development that enables cells to survive, proliferate and metastasize. Other hallmarks of the disease
- Published in Emerging Targets, HTS Assays